Global Stroke market is projected to register a CAGR of 7.5% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.
Market Segmentation
Global Stroke Market, By Type (Ischemic Stroke, Transient Ischemic Attack (TIA) and Hemorrhage Stroke), Diagnosis (Imaging Test, Blood Test, Echocardiogram, Lumbar Puncture, and Other), Treatment (Medication, Other Therapy, and Surgery), Gender (Female and Male), End-User (Hospitals & Clinics, Specialty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories and Others), Distribution Channel (Direct Tender, Retail Sales And Online Sales) Country (U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, Rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, UAE, South Africa, Egypt, Qatar, Kuwait, Oman, Bahrain and Rest of Middle East And Africa) - Industry trends and forecast to 2030.
Overview of Global Stroke Market Dynamics
- Drivers
- Rising incidences of stroke
- Increasing number of patients with hypertension and coronary heart diseases
- Restraints
- High cost associated with treatment of stroke
- Side-effects associated with medication
- Opportunities
- Expansion of telemedicine and remote monitoring
- Innovative therapies in pipeline for stroke treatment
Market Players
Some of the major market players operating in the global stroke market are:
- Bristol-Myers Squibb Company
- Boehringer Ingelheim International GmbH.
- F. Hoffmann-La Roche Ltd
- DAIICHI SANKYO COMPANY, LIMITED.
- Sanofi
- Johnson & Johnson Services, Inc.
- Bayer AG
- Sandoz AG
- Pfizer Inc.
- Medtronic
- Abbott
- Viatris Inc.
- AstraZeneca
- Penumbra, Inc.
- GLENMARK PHARMACEUTICALS LTD
- Fresenius Kabi USA
- Teva Pharmaceuticals USA, Inc.
- Lupin
- Amneal Pharmaceuticals LLC.
- Oxford Laboratories Pvt. Ltd.
TABLE OF CONTENTS
1 INTRODUCTION 81
- 1.1 OBJECTIVES OF THE STUDY 81
- 1.2 MARKET DEFINITION 81
- 1.3 OVERVIEW OF THE GLOBAL STROKE MARKET 81
- 1.4 LIMITATIONS 83
- 1.5 MARKETS COVERED 83
2 MARKET SEGMENTATION 88
- 2.1 MARKETS COVERED 88
- 2.2 GEOGRAPHICAL SCOPE 89
- 2.3 YEARS CONSIDERED FOR THE STUDY 90
- 2.4 CURRENCY AND PRICING 90
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 91
- 2.6 MULTIVARIATE MODELLING 94
- 2.7 TYPE LIFELINE CURVE 95
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 96
- 2.9 DBMR MARKET POSITION GRID 97
- 2.10 MARKET APPLICATION COVERAGE GRID 98
- 2.11 VENDOR SHARE ANALYSIS 99
- 2.12 SECONDARY SOURCES 100
- 2.13 ASSUMPTIONS 100
3 EXECUTIVE SUMMARY 101
4 PREMIUM INSIGHTS 104
- 4.1 PESTEL'S MODEL 107
- 4.2 PORTER'S 5 FORCES 108
5 EPIDEMIOLOGY 109
6 GLOBAL STROKE MARKET, REGULATORY FRAMEWORK 110
- 6.1 REGULATION IN U.S. 110
- 6.2 REGULATION IN EUROPE 111
- 6.3 REGULATION IN CHINA 112
- 6.4 REGULATION IN JAPAN 113
- 6.5 REGULATION IN SOUTH AFRICA 114
7 MARKET OVERVIEW 115
- 7.1 DRIVERS 117
- 7.1.1 RISING INCIDENCES OF STROKE 117
- 7.1.2 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASES 118
- 7.1.3 INCREASING DIABETIC AND OBESE POPULATION 119
- 7.1.4 ADVANCEMENTS IN MEDICAL TECHNOLOGY FOR STROKE TREATMENT 120
- 7.2 RESTRAINTS 121
- 7.2.1 HIGH COST ASSOCIATED WITH TREATMENT OF STROKE 121
- 7.2.2 SIDE-EFFECTS ASSOCIATED WITH MEDICATION 122
- 7.3 OPPORTUNITIES 123
- 7.3.1 EXPANSION OF TELEMEDICINE AND REMOTE MONITORING 123
- 7.3.2 INNOVATIVE THERAPIES IN PIPELINE FOR STROKE TREATMENT 123
- 7.4 CHALLENGES 124
- 7.4.1 INACCURATE DIAGNOSIS OF STROKES S 124
- 7.4.2 COMPLICATIONS IN MANAGING STROKE IN PATIENTS WITH MULTIPLE CHRONIC CONDITIONS 125
8 GLOBAL STROKE MARKET, BY TYPE 126
- 8.1 OVERVIEW 127
- 8.2 ISCHEMIC STROKE 130
- 8.2.1 THROMBOTIC (CEREBRAL THROMBOSIS) 131
- 8.2.2 EMBOLIC (CEREBRAL EMBOLISM) 131
- 8.3 HEMORRHAGIC STROKE 132
- 8.3.1 SUBARACHNOID HEMORRHAGE 133
- 8.3.2 INTRACEREBRAL HEMORRHAGE 133
- 8.4 TRANSIENT ISCHEMIC ATTACK (TIA) 133
9 GLOBAL STROKE MARKET, BY TREATMENT 134
- 9.1 OVERVIEW 135
- 9.2 MEDICATION 138
- 9.2.1 BY CLASS 139
- 9.2.1.1 BLOOD PRESSURE MEDICINES 140
- 9.2.1.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 141
- 9.2.1.1.1.1 RAMIPRIL 141
- 9.2.1.1.1.2 LISINOPRIL 141
- 9.2.1.1.1.3 ENALAPRIL 141
- 9.2.1.1.1.4 PERINDOPRIL 141
- 9.2.1.1.1.5 OTHER 142
- 9.2.1.1.2 DIURETICS 142
- 9.2.1.1.2.1 INDAPAMIDE 142
- 9.2.1.1.2.2 BENDROFLUMETHIAZIDE 142
- 9.2.1.1.2.3 SPIRONOLACTONE 142
- 9.2.1.1.2.4 AMILORIDE 143
- 9.2.1.1.2.5 OTHER 143
- 9.2.1.1.3 CALCIUM CHANNEL BLOCKERS 143
- 9.2.1.1.3.1 AMLODIPINE 143
- 9.2.1.1.3.2 NIFEDIPINE 143
- 9.2.1.1.3.3 VERAPAMIL 144
- 9.2.1.1.3.4 NICARDIPINE 144
- 9.2.1.1.3.5 FELODIPINE 144
- 9.2.1.1.3.6 NIMODIPINE 144
- 9.2.1.1.3.7 OTHER 144
- 9.2.1.1.4 BETA BLOCKERS 145
- 9.2.1.1.4.1 ATENOLOL 145
- 9.2.1.1.4.2 BISOPROLOL 145
- 9.2.1.1.4.3 LABETOLOL 145
- 9.2.1.1.4.4 OTHER 145
- 9.2.1.1.5 ALPHA BLOCKERS 146
- 9.2.1.1.5.1 DOXAZOSIN 146
- 9.2.1.1.5.2 OTHER 146
- 9.2.1.1.6 OTHERS 146
- 9.2.1.1 ANTIPLATELET DRUGS 147
- 9.2.1.1.1 ASPIRIN 147
- 9.2.1.1.2 CLOPIDOGREL 147
- 9.2.1.1.3 DIPYRIDAMOLE 147
- 9.2.1.1.4 TICLOPIDINE 147
- 9.2.1.1.5 OTHERS 147
- 9.2.1.2 ANTICOAGULANTS 148
- 9.2.1.2.1 WARFARIN 148
- 9.2.1.2.2 APIXABAN 148
- 9.2.1.2.3 DABIGATRAN 148
- 9.2.1.2.4 HEPARIN 148
- 9.2.1.2.5 RIVAROXABAN 149
- 9.2.1.2.6 OTHERS 149
- 9.2.1.3 TISSUE PLASMINOGEN ACTIVATOR (TPA) 149
- 9.2.1.3.1 ALTEPLASE 149
- 9.2.1.3.2 TENECTEPLASE 149
- 9.2.1.3.3 RETEPLASE 149
- 9.2.1.3.4 ANISTREPLASE 150
- 9.2.1.3.5 OTHERS 150
- 9.2.1.4 STATINS 150
- 9.2.1.4.1 ATORVASTATIN 150
- 9.2.1.4.2 SIMVASTATIN 150
- 9.2.1.4.3 LOVASTATIN 150
- 9.2.1.4.4 ROSUVASTATIN 151
- 9.2.1.4.5 FLUVASTATIN 151
- 9.2.1.4.6 PRAVASTATIN 151
- 9.2.1.4.7 PITAVASTATIN 151
- 9.2.1.4.8 OTHERS 151
- 9.2.1.5 VITAMIN K 151
- 9.2.1.6 SUPPORTIVE MEDICATION 152
- 9.2.1.6.1 NUTRITIONAL SUPPLEMENTS 152
- 9.2.1.6.2 ANTIPYRETICS 152
- 9.2.1.6.3 OTHERS 152
- 9.2.2 BY DRUG TYPE 153
- 9.2.2.1 GENERICS 153
- 9.2.2.2 BRANDED 154
- 9.2.2.2.1 ELIQUIS 154
- 9.2.2.2.2 PRADAXA 154
- 9.2.2.2.3 ACTIVASE 154
- 9.2.2.2.4 ASPIRIN 155
- 9.2.2.2.5 PLAVIX 155
- 9.2.2.2.6 AGGRENOX 155
- 9.2.2.2.7 OTHERS 155
- 9.2.3 BY ROUTE OF ADMINISTRATION 156
- 9.2.3.1 ORAL 156
- 9.2.3.1.1 TABLET 157
- 9.2.3.1.2 CAPSULES 157
- 9.2.3.1.3 Others 157
- 9.2.3.2 PARENTERAL 158
- 9.2.3.2.1 INTRAVENOUS 158
- 9.2.3.2.2 SUBCUTANEOUS 158
- 9.2.3.3 OTHERS 158
- 9.2.4 BY MODE OF PURCHASE 159
- 9.2.4.1 PRESCRIPTION 159
- 9.2.4.2 OVER THE COUNTER (OTC) 159
- 9.2.5 BY THERPAY TYPE 160
- 9.2.5.1 COMBINATION THERAPY 160
- 9.2.5.2 MONOTHERAPY 160
- 9.3 SURGERY 161
- 9.3.1 EMBOLIC COILS 162
- 9.3.2 ASPIRATION CATHETERS 162
- 9.3.3 STENT RETRIEVER 162
- 9.3.4 SURGICAL CLIPPING 162
- 9.3.5 OTHERS 162
- 9.4 OTHER THERAPY 163
- 9.4.1 PHYSICAL THERAPY 163
- 9.4.2 OCCUPATIONAL THERAPY 163
- 9.4.3 SPEECH THERAPY 164
- 9.4.4 OTHERS 164
10 GLOBAL STROKE MARKET, BY DIAGNOSIS 165
- 10.1 OVERVIEW 166
- 10.2 IMAGING TEST 169
- 10.2.1 COMPUTERIZED TOMOGRAPHY (CT) SCAN 169
- 10.2.2 MAGNETIC RESONANCE IMAGING (MRI) 170
- 10.2.3 CAROTID ULTRASOUND 170
- 10.2.4 CEREBRAL ANGIOGRAM 170
- 10.3 BLOOD TEST 171
- 10.4 ECHOCARDIOGRAM 171
- 10.5 LUMBAR PUNCTURE 172
- 10.6 OTHERS 172
11 GLOBAL STROKE MARKET, BY GENDER 173
- 11.1 OVERVIEW 174
- 11.2 FEMALE 177
- 11.3 MALE 178
12 GLOBAL STROKE MARKET, BY END USER 179
- 12.1 OVERVIEW 180
- 12.2 HOSPITALS & CLINICS 183
- 12.3 SPECIALTY CLINICS 184
- 12.4 AMBULATORY SURGICAL CENTER 184
- 12.5 HOMECARE 185
- 12.6 LABORATORIES 185
- 12.7 OTHERS 186
13 GLOBAL STROKE MARKET, BY DISTRIBUTION CHANNEL 187
- 13.1 OVERVIEW 188
- 13.2 DIRECT 191
- 13.3 RETAIL 191
- 13.4 ONLINE 192
14 GLOBAL STROKE MARKET, BY REGION 193
- 14.1 OVERVIEW 194
- 14.2 NORTH AMERICA 197
- 14.2.1 U.S. 209
- 14.2.2 CANADA 220
- 14.2.3 MEXICO 231
- 14.3 EUROPE 242
- 14.3.1 GERMANY 255
- 14.3.2 U.K. 266
- 14.3.3 FRANCE 277
- 14.3.4 RUSSIA 289
- 14.3.5 ITALY 301
- 14.3.6 SPAIN 313
- 14.3.7 TURKEY 325
- 14.3.8 POLAND 336
- 14.3.9 BELGIUM 347
- 14.3.10 NETHERLANDS 358
- 14.3.11 SWITZERLAND 369
- 14.3.12 DENMARK 381
- 14.3.13 SWEDEN 392
- 14.3.14 NORWAY 403
- 14.3.15 FINLAND 415
- 14.3.16 REST OF EUROPE 427